Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke ambulance trial aims to cut disability from brain bleeds

NCT ID NCT07665827

Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether giving blood pressure medication inside a mobile stroke unit—a special ambulance with a CT scanner—can improve outcomes for people having a brain bleed. About 706 adults with high blood pressure and a recent stroke will be randomly assigned to either the mobile unit or standard emergency care. The goal is to see if faster treatment reduces disability or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
urapidil (blood pressure medication)
What this could lead to
If it works, this could show that starting blood pressure treatment in a mobile stroke unit reduces disability after a brain bleed.
What could go wrong
This is an early-stage trial, and the treatment may not improve outcomes or could cause side effects like low blood pressure. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 706 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. History and physical/neurological examination consistent with acute stroke. 2. Age ≥18 years; 3. Time from symptom onset to enrollment \<3 hours (onset defined as last known normal). 4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg; 5. Pre-stroke modified Rankin Scale (mRS) score ≤2; 6. Informed consent obtained from the subject or a legally authorized representative. Exclusion Criteria: 1. Glasgow Coma Scale (GCS) score ≤5. 2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease. 3. Malignant disease or other serious primary illness with a life expectancy of \<3 months. 4. Current participation in another interventional randomized clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder cerebrovascular disorder Hemorrhage Hemorrhagic Stroke intracerebral hemorrhage Intracranial Hemorrhage, Hypertensive Intracranial Hemorrhages nervous system disorder stroke disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Cerebral hemorrhage Cerebral hemorrhage, hypertensive Cerebrovascular disorders Hemorrhage Hemorrhagic stroke, intracerebral Intracranial hemorrhages Nervous system diseases Stroke Vascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xuanwu Hospital

    Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.